QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01315249 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

523

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: indacaterol and glycopyrronium (QVA149)
DRUG: Placebo to fluticasone/salmeterol
DRUG: fluticasone/salmeterol
DRUG: Placebo to indacaterol and glycopyrronium (QVA149)

Sponsor

Novartis Pharmaceuticals